<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121261</url>
  </required_header>
  <id_info>
    <org_study_id>070219812014</org_study_id>
    <nct_id>NCT03121261</nct_id>
  </id_info>
  <brief_title>The Effect of Local Anesthetic and Clonidine on the Cutaneous Silent Period During Spinal Anesthesia</brief_title>
  <official_title>The Effect of Local Anesthetic and Clonidine on the Cutaneous Silent Period During and After Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Dubrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Dubrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cutaneous silent period is a non-invasive technique that gives insight into the function
      of thin A delta fibers and as such can be a complement to conventional electrophysiological
      methods used to study the peripheral nerves. Clonidine is a selective partial agonist of the
      alpha-2 receptors which, added intrathecally to levobupivacaine, enhances the effect of a
      local anesthetic, prolongs sensory and motor block during local anesthesia and extends the
      length of post-operative analgesia. It is believed that clonidine achieves this effect by
      activating the postsynaptic alpha-2 receptors in the gelatine substance of the spinal cord
      and blocking the conduction of A-delta and C fibers. The aim of the study is to examine
      functional changes of Aδ - fibers during the application of spinal anesthesia by measuring
      the cutaneous slinet period and compare the effect of intrathecal administration of a
      combination of local anesthetic and clonidine in the quiet skin period in relation to the
      application of local anesthetic only.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4 Item Duration of Latency and duration of the cutaneous silent period</measure>
    <time_frame>24 hours perioperative</time_frame>
    <description>Duration of latency and duration of the cutaneous silent (msec) period before subarahnoid block, after regression of motor block, sixth hour of intrathecal administration, 24 hours after intrathecal administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>24 hours perioperative</time_frame>
    <description>The duration of motor block and its regression will be monitored by Bromage scale:0- Bromage patient can perform movements in the hip, knee and foot. Bromage 1-patient can not perform movements in the hip, but can flexes the knee and move the foot, Bromage 2- patient can not perform movements in the hip and knee, but can move a foot. Bromage 3- patient can not perform movements in the hip, knee nor move the foot. The time of intrathecal levobupivacaine solution or levobupivacaine and clonidine solution is considered to be time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of sensory block</measure>
    <time_frame>24 hours perioperative</time_frame>
    <description>The time needed for the regression of sensory block in two dermatome will be measured; the time (min) required for a regression in the S1 dermatome, the time required to restore motor functions in Bromage 0 and the duration of analgesia(min).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inguinal Hernia</condition>
  <condition>Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>0.5% levobupivacaine with 0.015% clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% levobupivacaine with 0.9% saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaine</intervention_name>
    <description>Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml</description>
    <arm_group_label>0.5% levobupivacaine with 0.015% clonidine</arm_group_label>
    <arm_group_label>0.5% levobupivacaine with 0.9% saline</arm_group_label>
    <other_name>chirocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine</intervention_name>
    <description>Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml</description>
    <arm_group_label>0.5% levobupivacaine with 0.015% clonidine</arm_group_label>
    <arm_group_label>0.5% levobupivacaine with 0.9% saline</arm_group_label>
    <other_name>catapressan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ASA one and two status BMI 18,5 to 24

        Exclusion Criteria:

        Coagulation disorders Polyneuropathy Diabetes mellitus Alcoholism Systemic inflammatory and
        malignant diseases Stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Inghilleri M, Cruccu G, Argenta M, Polidori L, Manfredi M. Silent period in upper limb muscles after noxious cutaneous stimulation in man. Electroencephalogr Clin Neurophysiol. 1997 Apr;105(2):109-15.</citation>
    <PMID>9152203</PMID>
  </reference>
  <reference>
    <citation>Mota IA, Fernandes JB, Cardoso MN, Sala-Blanch X, Kofler M, Valls-Solé J. Temporal profile of the effects of regional anesthesia on the cutaneous reflexes of foot muscles. Exp Brain Res. 2015 Sep;233(9):2587-96. doi: 10.1007/s00221-015-4329-2. Epub 2015 May 30.</citation>
    <PMID>26025613</PMID>
  </reference>
  <results_reference>
    <citation>Uncini A, Kujirai T, Gluck B, Pullman S. Silent period induced by cutaneous stimulation. Electroencephalogr Clin Neurophysiol. 1991 Oct;81(5):344-52.</citation>
    <PMID>1718720</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Dubrava</investigator_affiliation>
    <investigator_full_name>Sandra Graf Zupcic</investigator_full_name>
    <investigator_title>Neurology Specialist</investigator_title>
  </responsible_party>
  <keyword>levobupivacaine</keyword>
  <keyword>nerve fibers</keyword>
  <keyword>clonidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

